Cybin

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that it has received a “may proceed letter” and Investigational New Drug Application (“IND”) clearance from the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003. CYB003 is a proprietary deuterated psilocybin analog that is being developed for the

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights. The Company also reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board in recent months, accelerating both our pipeline o

Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 1st Annual Mental Health Conference being held at the Lotte New York Palace Hotel on June 27, 2022. Mr. Drysdale's fireside chat will be webcast live on Monday, June 27, 2022 at 10:30

Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has received Institutional Review Board (“IRB”) approval to begin the first-in-human Phase 1/2a clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “IRB approval of our trial protocol is a significant regulatory

Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”) to accelerate the clinical development path for CYB00

Cybin Acquires DMT Clinical Study from Entheon Biomedical

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii), (iii) as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “Transaction Ag

Cybin Announces Additional Adelia Milestone Achievements

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company's EMBARK Psychedelic Facilitator Training Program. Recognizing the crucial importance of supporting psychedelic study facilitators with quality training, Cybin has brought together recognized leaders and senior psychedelic-assisted

Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, is pleased to announce the publication of a peer-reviewed article introducing EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. “It's a pleasure to see our work published in this respec

Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its Phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the

Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Catalyst Biosciences

Jaguar Health

Kala Pharmaceuticals

Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 To Watch Under $1

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that it will participate in the morning trading bell ceremony on May 18, 2022 at the New York Stock Exchange (“NYSE”) in New York City. Cybin, whose shares commenced trading on the NYSE American on August 5, 2021, was the first psychedelics company to be listed on the NYSE. “We are delighted to be

Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference being held at the Fontainebleau Miami Beach May 23-26, 2022. Mr. Drysdale's fireside chat will be webcast live on Wednesday, May 25, 2022 at 12:30

Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022

LOS ANGELES & TORONTO--(BUSINESS WIRE)-- #biotech--Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine's Effects on the Brain

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the ‘From Research to Reality' Global Summit on Psychedelic-Assisted Therapies and Medicines taking place May 27-29, 2022, in Toronto, Canada. The poster is titled Pha

Cybin Announces CYB003 Poster to be Presented at the ‘From Research to Reality' Global Summit on Psychedelic-Assisted Therapies and Medicine

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the KCSA Psychedelics Virtual Investor Conference at 11:00 a.m. ET on Thursday, April 28, 2022. This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. To participate

Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that it has partnered with Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company's Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Adobe

Atai Life Sciences BV

COMPASS Pathways

Delta Air Lines

GW Pharmaceuticals

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Lowe's

Mind Medicine MindMed

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

VANCOUVER, BC / ACCESSWIRE / April 13, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Cybin and Baroyeca Gold & Silver on their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives.

The Power Play by The Market Herald Releases Interviews with Cybin and Baroyeca Gold & Silver

Artelo Biosciences Inc

Meten Holding Group Ltd.

ProQR Therapeutics

Sonnet BioTherapeutics

Statera Biopharma Inc

Exela Technologies

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 Stocks Under $1 With Big News Today

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004, delivered via inhalation. Specifically, inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including longer duration of action, and imp

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (PCT) patent application no.PCT/EP2021/077057), further strengthening its long-term intell

Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules

Field Trip Health Ltd

Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. The post 3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill appeared first on InvestorPlace.

3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel's quantitative neuroimaging technology, Flow, to measure ketamine's psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment,

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain

TORONTO--(BUSINESS WIRE)--Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003

Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

TORONTO--(BUSINESS WIRE)--Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

Cybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting Participants

News for Cybin Stock (CYBN)